Onconova is planning a sideways step for its lead cancer drug rigosertib—with help from a research consortium—that could open up new opportunities in rare…
The series B equips the biotech to take its lead treatment for multidrug-resistant Gram‐negative infections through clinical trials.
With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes.…
Monday's dose of FierceBiotech's news of note.
A multipronged immune attack that includes CAR-T treatments may be needed to fight glioblastoma, Penn scientists suggest.
Celgene has announced a new arm of a phase 1b study that will study Novocure’s noninvasive brain cancer therapy alongside a pair of cancer drugs.
Sarepta CEO Doug Ingram aims to raise $250 million in a public stock offering as the company looks beyond its first product, DMD therapy Exondys 51.
The outlay gives Lilly the rights to a drug designed to treat autoimmune diseases by boosting the number and activity of regulatory T cells.
Mitsubishi Tanabe is to spend $1.1 billion on Parkinson’s disease biotech NeuroDerm as it looks to boost its U.S. presence and CNS pipeline.
The drug failed to improve progression-free survival in mesothelioma, causing the stocks of Bayer’s collaborators ImmunoGen and MorphoSys to slip.
Fresh from the news that its lead pipeline candidate is back under FDA review with a verdict due before year-end, Aeterna has just announced the departure of…